BIB vs. LABU
BIB (ProShares Ultra Nasdaq Biotechnology) and LABU (Direxion Daily S&P Biotech Bull 3x Shares) are both Leveraged Equities funds - BIB tracks the NASDAQ Biotechnology Index (200%) while LABU tracks the S&P Biotechnology Select Industry Index (300%). Both are passively managed. Over the past 10 years, BIB returned 9.71%/yr vs -7.18%/yr for LABU. Their correlation of 0.92 suggests significant overlap in exposure. BIB charges 0.95%/yr vs 1.12%/yr for LABU.
Performance
BIB vs. LABU - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 12.50% return, which is significantly lower than LABU's 47.57% return. Over the past 10 years, BIB has outperformed LABU with an annualized return of 9.71%, while LABU has yielded a comparatively lower -7.18% annualized return.
BIB
- 1D
- 1.97%
- 1M
- 9.49%
- YTD
- 12.50%
- 6M
- 8.62%
- 1Y
- 100.86%
- 3Y*
- 19.65%
- 5Y*
- -0.74%
- 10Y*
- 9.71%
LABU
- 1D
- 2.26%
- 1M
- 34.26%
- YTD
- 47.57%
- 6M
- 36.98%
- 1Y
- 324.35%
- 3Y*
- 23.36%
- 5Y*
- -31.01%
- 10Y*
- -7.18%
BIB vs. LABU - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 12.50% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
LABU Direxion Daily S&P Biotech Bull 3x Shares | 47.57% | 79.17% | -26.02% | -13.41% | -80.36% | -64.15% | 74.66% | 75.50% | -57.61% | 149.12% |
Correlation
The correlation between BIB and LABU is 0.93, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.93 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.92 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.91 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.92 |
Correlation (All Time) Calculated using the full available price history since May 28, 2015 | 0.92 |
The correlation between BIB and LABU has been stable across timeframes, ranging from 0.91 to 0.93 - a consistent structural relationship.
BIB vs. LABU - Sectors Allocation Comparison
Sectors
BIB
LABU
Healthcare
Financial Services
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
BIB
LABU
Financial Services
BIB
LABU
Basic Materials
BIB
-
LABU
Communication Services
BIB
-
LABU
-
Consumer Cyclical
BIB
-
LABU
-
Consumer Defensive
BIB
-
LABU
-
Energy
BIB
-
LABU
-
Industrials
BIB
-
LABU
-
Real Estate
BIB
-
LABU
-
Technology
BIB
-
LABU
-
Utilities
BIB
-
LABU
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. LABU — Risk / Return Rank
BIB
LABU
BIB vs. LABU - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | LABU | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.64 | ||
| Sortino ratioReturn per unit of downside risk | -0.59 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.44 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.99 | 10.64 | -4.65 |
| Martin ratioReturn relative to average drawdown | 18.30 | 29.90 | -11.60 |
Loading charts...
Drawdowns
BIB vs. LABU - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum LABU drawdown of -99.18%. Use the drawdown chart below to compare losses from any high point for BIB and LABU.
Loading charts...
Drawdown Indicators
| BIB | LABU | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -99.18% | +31.94% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -30.70% | +13.78% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -78.30% | +33.00% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -97.59% | +31.73% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -98.96% | +32.76% |
Current DrawdownCurrent decline from peak | -17.29% | -94.80% | +77.51% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -81.72% | +49.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 10.91% | -5.38% |
Volatility
BIB vs. LABU - Volatility Comparison
The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 13.56%, while Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a volatility of 29.76%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than LABU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | LABU | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.56% | 29.76% | -16.20% |
Volatility (6M)Calculated over the trailing 6-month period | 31.65% | 63.07% | -31.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.43% | 78.78% | -38.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.60% | 95.94% | -52.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.39% | 95.44% | -49.05% |
BIB vs. LABU - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is lower than LABU's 1.12% expense ratio.
Dividends
BIB vs. LABU - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.55%, more than LABU's 0.52% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.55% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LABU Direxion Daily S&P Biotech Bull 3x Shares | 0.52% | 0.84% | 0.35% | 0.35% | 0.00% | 0.00% | 0.00% | 0.28% | 0.64% | 0.17% |
Frequently Asked Questions
With a correlation of 0.93, BIB and LABU move almost identically. Holding both adds very little diversification - you're essentially doubling your position in the same market segment. Choosing one is usually more capital-efficient.
LABU has higher volatility (29.76%) compared to BIB (13.56%). In terms of maximum drawdown, BIB dropped -67.24% vs LABU's -99.18%.
On 10-year performance, BIB leads with 9.71% vs -7.18% for LABU. On fees, BIB is cheaper at 0.95% per year. On volatility, BIB has been the lower-risk option at 13.56%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BIB has performed better with a 9.71% return vs -7.18%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
BIB is cheaper with a 0.95% expense ratio, compared with 1.12% for LABU.
BIB has the higher dividend yield at 0.55%, compared with 0.52% for LABU.
BIB tracks NASDAQ Biotechnology Index (200%), while LABU tracks S&P Biotechnology Select Industry Index (300%). They also come from different issuers: ProShares and Direxion. Their fees differ too: 0.95% for BIB and 1.12% for LABU.
LABU currently has the higher Sharpe Ratio (4.15 vs 2.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and LABU
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer